Package Insert: Information for the User
Donepezilo Mabo 10 mg Film-Coated Tablets EFG
Donepezil Hydrochloride
Read this package insert carefully before starting to take this medication, as it contains important information for you.
Keep this package insert, as you may need to refer to it again.
1.What isDonepezilo Maboand for what it is used
2.Before taking Donepezilo Mabo
3. How to takeDonepezilo Mabo
4. Possible adverse effects
5. Storage ofDonepezilo Mabo
6. Contents of the package and additional information.
Donepezilo Mabo belongs to a group of medications known as cholinesterase inhibitors.
Donepezilo Mabo is used to treat the symptoms of dementia in individuals with a diagnosis ofmild to moderately severe Alzheimer's disease. It is used only in adult patients.
- if you are allergic (hypersensitive) to donepezil hydrochloride, related substances (piperidine derivatives) or any of the other components of Donepezilo Mabo.
(see section 6, Additional information).
Be especially careful with Donepezilo Mabo:
Check if any of the warnings in the following list apply or have applied to your case.Inform your doctor:
Use of other medications
Other medications may be affected by donepezil hydrochloride. They, in turn, may affect the action of donepezil hydrochloride. This may interact with:
Especially, it is essential to inform your doctor if you are taking any of the following types of medications:
over-the-counter medications, for example, herbal remedies
Inform your doctor or pharmacistif you are using or have recently used other medications, including those obtained without a prescription.
Taking Donepezilo Mabo with food and drinks
Alcohol may reduce the effect of donepezil hydrochloride. Therefore, be careful when usingalcoholand donepezil hydrochloride at the same time.
Pregnancy and breastfeeding
No sufficient data are available to evaluate the efficacy of donepezil hydrochloride during breastfeeding.Do not breastfeedwhile taking donepezilo.
Consult your doctor or pharmacist before using any medication.
Driving and operating machinery
Alzheimer's disease may alter the ability to drive or operate machinery, and you should not perform these activities unless your doctor tells you it is safe to do so.
Additionally, DonepeziloMabomay causefatigue, dizziness, and muscle crampsand, if you are affected, you should not drive or operate machinery.
Donepezilo Mabo contains lactose
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medication.
Follow exactly the administration instructions for Donepezilo Mabo indicated by your doctor. Consult your doctor or pharmacist if you have any doubts.
Inform your doctor or pharmacist of the person in charge of your care. This will help them take the medication as prescribed.
The dose of the tablet you take may change, depending on the time you have been taking the medication and what your doctor recommends.
The usual doseis one film-coated tablet of Donepezilo Mabo 5 mg (5 mg of donepezilo hydrochloride) at night. After a month, your doctor may tell you to take two film-coated tablets of Donepezilo Mabo 5 mg (10 mg of donepezilo hydrochloride) at night. If you experience abnormal dreams, nightmares, or difficulty sleeping (see section 4), your doctor may recommend taking Donepezilo Mabo in the morning. The maximum recommended dose is 10 mg at night.
No dose adjustment is required if you have kidney problems.
If you havemild or moderate liver problems, your doctor will need to adjust the dose gradually and carefully according to your needs. If you have severe liver problems, you should be more careful with Donepezilo Mabo (see section 2, "Before taking Donepezilo Mabo"). If you have an unexplained liver disease, your doctor may decide to completely stop treatment with donepezilo hydrochloride.
This medication is not recommended for children and adolescents (under 18 years old).
How to take it:Take the Donepezilo tablet by mouth, with a sip of water, at night, before going to bed.
Your doctor will tell you for how long you should continue taking the tablets. You should visit your doctor at regular intervals for them to review your treatment and evaluate your symptoms.
If you take more Donepezilo Mabo than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount taken.
Do not take a larger dose than you should. If you take more donepezilo than you should, you may experience symptoms such as nausea, vomiting, salivation, sweating, slow heart rate (bradycardia), low blood pressure (hypotension), breathing difficulties (respiratory depression), muscle weakness (collapse), and involuntary muscle contractions (convulsions), as well as increased muscle weakness, a possibly fatal condition.
If you have taken more tablets than you should, consult your doctor or pharmacist immediately.
If you forget to take Donepezilo Mabo
Do not take a double dose to make up for a missed dose. Skip the missed dose and take the next tablet at the usual dose the next day. If you forget to take your medication for more than a week, call your doctor before taking more medication.
If you interrupt treatment with Donepezilo Mabo
Do not stop taking your tablets, even if you feel well, unless your doctor tells you to.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Adverse effects may be:
Additional investigations
Uncommon: minor increase in serum concentration of certain muscle enzyme (creatine kinase).
Heart(cardiac disorders)
Uncommon: slow heart rate (bradycardia).
Rare: certain heart conduction disorders that cause arrhythmia (sinoatrial block, atrioventricular block).
Unknown frequency: changes in cardiac activity that may be observed on an electrocardiogram (ECG) called "prolongation of the QT interval", rapid and irregular heartbeat, fainting that may be a symptom of a potentially life-threatening condition known as torsades de pointes
Nervous system(neurological disorders)
Common: fainting (syncope), dizziness, inability to sleep (insomnia).
Uncommon: seizures.
Rare: uncontrolled body or facial movements (extrapyramidal symptoms).
Stomach and intestines (gastrointestinal disorders).
Very common: diarrhea, nausea.
Common: vomiting, abdominal disorders. Uncommon: internal bleeding (gastrointestinal hemorrhage), ulcers (gastric and duodenal ulcers).
Unknown frequency (cannot be estimated from available data): Pisa syndrome (a condition that involves involuntary muscle contraction with abnormal flexion of the body and head to one side).
Kidney(renal and urinary disorders)
Common: urinary incontinence.
Skin(skin and subcutaneous tissue disorders)
Common: skin rash, itching (pruritus).
Muscles (musculoskeletal and connective tissue disorders)
Common: muscle cramps.
Food(metabolic and nutritional disorders)
Common: loss of appetite (anorexia).
Infections(infections and infestations)
Common: common cold.
Accidents, poisoning and complications of therapeutic procedures: Common: accidents.
General(general disorders and administration site conditions)
Very common: headache.
Common: fatigue, pain.
Liver(hepatobiliary disorders)
Rare: liver dysfunction, including hepatitis.
Mental(psychiatric disorders)
Common: imagining things that do not exist (hallucinations), agitation, aggressive behavior.
Unknown frequency (cannot be estimated from available data): increased libido, hypersexuality.
The doctor may decide to reduce the dose or stop treatment to resolve these adverse effects.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of medicinal products for human use, https://www.notificaRAM.es.By reporting adverse effects, you can contribute to providing more information on the safety of this medication
Keep out of the reach and sight of children.
Do not use Donepezilo Mabo after the expiration date that appears on the blister pack and on the outer carton, after CAD. The first two digits indicate the month, and the last four digits indicate the year. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Do not dispose of the medication through the drains or in the trash. Dispose of the packaging and unused medication at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medication. By doing so, you will help protect the environment.
Composition of Donepezilo Mabo
- The active ingredient is donepezilo hydrochloride.
Cada comprimido recubierto con película contiene 10 mg of donepezilo hydrochloride,
equivalente a 9,12 mg of donepezilo.
- The other components are:
Núcleo del comprimido:
Lactose monohydrate
Maize starch
Microcrystalline cellulose
Hydroxypropyl cellulose
Magnesium stearate
Recubierta de película:
10 mg:
Hydroxypropyl methylcellulose
Titanium dioxide (E171)
Propylene glycol
Povidone (K25)
Yellow iron oxide (E172)
Appearance of Donepezilo Mabo 10 mg and content of the container
DonepeziloMabo10 mg Film-coated tablets are yellow, round, biconvex film-coated tablets.
This medicine is presented in blisters of 7, 14, 28, 30, 50, 56, 60, 84, 98, 100, 112 or 120
film-coated tablets.
Only some sizes of packaging may be commercially marketed.
Marketing Authorization Holder
MABO-FARMA S.A.
Calle Rejas 2, planta 1
28821 Coslada (Madrid)
Spain
Responsible for manufacturing
Infarmade S.L
C/ Torre de los Herberos nº 35
Pol. Ind. “Carretera de la Isla”
41703 Dos Hermanas
Sevilla
O
NETPHARMALAB CONSULTING SERVICES
Carretera de Fuencarral 22, Alcobendas, 28108, Madrid
This medicine is authorized in the member states of the European Economic Area with
the following names:
Spain: Donepezilo Mabo 10 mg Film-coated tablets
This leaflet has been approved in October 2022
The detailed and updated information of this medicine is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.